The CYRUS trial failed to demonstrate a significant decrease in the sequential organ failure assessment (SOFA) score at 24 h after nonshockable OHCA in patients receiving a prehospital single injection of 2.5 mg/kg CsA [[4]]. Even though this post-hoc analysis of the CYRUS trial does not provide mechanistic insight, our findings are in line with both experimental and clinical studies reporting potent protective effects of CsA against ischemia/reperfusion (I/R) injury [[1], [3], [5]]. [Extracted from the article]